Clinical Recognition, Safe Triage, and Pharmacovigilance Reporting Readiness for Suspected Serious Adverse Drug Reactions in Community Pharmacies: A Covert Simulated-Patient Study in Central Jordan
Journal of Clinical Medicine · 06.11.2026 · 15 (21) · 8652
DOI: 10.3390/jcm15218652 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.11.2026. Verfasst von Zekrayat J H Merdas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, College of Pharmacy, Amman Arab University, Amman 11953, Jordan. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah bint Abdulrahman University.
Abstract (Originalsprache)
Background/Objectives: Serious adverse drug reactions (ADRs) may first present with nonspecific symptoms outside hospital settings, where delayed recognition or escalation can postpone definitive care. Community pharmacists are often a first point of contact, but behavior-based evidence on their clinical recognition and triage of serious ADRs is limited. We evaluated clinical assessment, recognition, safe triage, and subsequent pharmacovigilance reporting readiness across three high-risk presentations.
Methods
A cross-sectional covert simulated-patient study was conducted in 384 urban community pharmacies in Amman, Zarqa, and Al-Balqa, Jordan. Pharmacies were randomly assigned one of three standardized scenarios: semaglutide-associated acute pancreatitis, empagliflozin-associated euglycemic diabetic ketoacidosis, or apixaban-associated gastrointestinal bleeding. The primary outcome was a guideline-informed safe-triage response requiring urgent ED/EMS referral, explicit communication of urgency, and no management likely to delay care; pharmacovigilance reporting behavior and readiness were assessed separately after completion of the clinical consultation.
Results
Safe triage occurred in 41.7% of encounters (design-based 95% CI, 37.0–46.3), with higher performance for apixaban (60.9%) than semaglutide (42.2%) and empagliflozin (21.9%; overall p < 0.001). A medication-related cause was recognized in 72.9%, whereas the specific syndrome or harm was named in 39.6%; unsafe management likely to delay assessment occurred in 26.3%. Only 8.3% spontaneously raised reporting. In adjusted analysis, safe triage was less prevalent in the empagliflozin scenario (aPR 0.51, 95% CI 0.35–0.74) and more prevalent in the apixaban scenario (aPR 1.54, 95% CI 1.21–1.96) than in the semaglutide reference scenario. High workload was associated with lower safe-triage prevalence, whereas a visible consultation area and recent pharmacovigilance training were associated with higher prevalence.
Conclusions
In urban community pharmacies in central Jordan, important gaps were observed in recognition, explicit escalation, and safe triage, particularly for the euglycemic ketoacidosis presentation. Spontaneous pharmacovigilance engagement was also limited. Interventions should prioritize drug-specific red-flag recognition, unambiguous escalation language, workflow support for focused assessment, and low-burden reporting after immediate patient safety has been addressed. These findings should not be generalized to rural pharmacies or other regions of Jordan without further evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacy Department, College of Pharmacy, Amman Arab University, Amman 11953, Jordan.
- Clinical Pharmacy Department, Faculty of Pharmacy, Zarqa University, Zarqa 13132, Jordan.
- Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19111, Jordan.
- Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman 11942, Jordan.
- Clinical Affairs Department, Qatar University, Doha 2713, Qatar.
- Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
ORCID-Profile: Zekrayat J H Merdas, Mohammad Abu Assab, Anas Abed, Zainab Zakaraya, Sireen Abdul Rahim Shilbayeh
Förderung
- Princess Nourah bint Abdulrahman University
Zitieren
APA
Merdas, Z. J. H., Abu Assab, M., Abed, A., Safadi, W. A., Zakaria, Z. Z., Zakaraya, Z., & Shilbayeh, S. A. R. (2026). Clinical Recognition, Safe Triage, and Pharmacovigilance Reporting Readiness for Suspected Serious Adverse Drug Reactions in Community Pharmacies: A Covert Simulated-Patient Study in Central Jordan. Journal of Clinical Medicine, 15(21), 8652. https://doi.org/10.3390/jcm15218652
Vancouver
Merdas ZJH, Abu Assab M, Abed A, Safadi WA, Zakaria ZZ, Zakaraya Z, et al. Clinical Recognition, Safe Triage, and Pharmacovigilance Reporting Readiness for Suspected Serious Adverse Drug Reactions in Community Pharmacies: A Covert Simulated-Patient Study in Central Jordan. Journal of Clinical Medicine. 2026;15(21):8652. doi:10.3390/jcm15218652
BibTeX
@article{Merdas2026,
author = {Merdas, Zekrayat J H and Abu Assab, Mohammad and Abed, Anas and Safadi, Wala'a Al and Zakaria, Zain Z and Zakaraya, Zainab and Shilbayeh, Sireen Abdul Rahim},
title = {Clinical Recognition, Safe Triage, and Pharmacovigilance Reporting Readiness for Suspected Serious Adverse Drug Reactions in Community Pharmacies: A Covert Simulated-Patient Study in Central Jordan},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8652},
doi = {10.3390/jcm15218652}
}
EUVIMED